Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313373552> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4313373552 endingPage "165.39" @default.
- W4313373552 startingPage "165.39" @default.
- W4313373552 abstract "Abstract Introduction The FDA recently approved Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, for first-line combinatory treatment in patients with extensive-stage small cell lung cancer. Across several cancer types, immunotherapy has been shown to provide durable benefit in patients with metastatic disease. However, Atezolizumab only improves overall survival by 2 months. This could be due to the fact that <20% of patients express >1% tumor PD-L1 positivity. We assert that a better understanding of this immune contexture – defined as abundance and type of checkpoint molecules in SCLC – may provide important criteria for patient stratification. Objectives In these studies, we will test the hypothesis that immune checkpoints in addition to the PD-1/PD-L1 axis play a role in immune evasion in SCLC. Methods To evaluate expression of immune checkpoint molecules, we acquired bulk RNA-Seq data of SCLC cell lines and primary tumor specimens. Further, we generated tissue-microarrays containing >20 unique cell lines and >200 unique patient specimens with fully annotated clinical data to confirm expression of these molecules by immunohistochemistry. Results Preliminary RNA-Seq analyses show low PD-L1 expression in SCLC cell lines and primary tumors. Further, ubiquitously high expression of certain checkpoint molecules (B7-H3) is seen. Future analysis will confirm abundance and type of checkpoint molecules as well as capture interpatient heterogeneity. Conclusions Understanding the checkpoint molecules present in SCLC could further understanding of SCLC immune suppression, ultimately leading to optimal single-agent immunotherapy deployment and rational, effective combination therapy for patients with SCLC." @default.
- W4313373552 created "2023-01-06" @default.
- W4313373552 creator A5003212140 @default.
- W4313373552 creator A5017151918 @default.
- W4313373552 creator A5018378822 @default.
- W4313373552 creator A5061250244 @default.
- W4313373552 creator A5062981077 @default.
- W4313373552 creator A5074068244 @default.
- W4313373552 date "2020-05-01" @default.
- W4313373552 modified "2023-09-27" @default.
- W4313373552 title "Evaluation of immune checkpoints in small cell lung cancer: implications for immunotherapy" @default.
- W4313373552 doi "https://doi.org/10.4049/jimmunol.204.supp.165.39" @default.
- W4313373552 hasPublicationYear "2020" @default.
- W4313373552 type Work @default.
- W4313373552 citedByCount "0" @default.
- W4313373552 crossrefType "journal-article" @default.
- W4313373552 hasAuthorship W4313373552A5003212140 @default.
- W4313373552 hasAuthorship W4313373552A5017151918 @default.
- W4313373552 hasAuthorship W4313373552A5018378822 @default.
- W4313373552 hasAuthorship W4313373552A5061250244 @default.
- W4313373552 hasAuthorship W4313373552A5062981077 @default.
- W4313373552 hasAuthorship W4313373552A5074068244 @default.
- W4313373552 hasConcept C121608353 @default.
- W4313373552 hasConcept C126322002 @default.
- W4313373552 hasConcept C143998085 @default.
- W4313373552 hasConcept C203014093 @default.
- W4313373552 hasConcept C2775949291 @default.
- W4313373552 hasConcept C2776256026 @default.
- W4313373552 hasConcept C2777701055 @default.
- W4313373552 hasConcept C2780030458 @default.
- W4313373552 hasConcept C2780674031 @default.
- W4313373552 hasConcept C2780851360 @default.
- W4313373552 hasConcept C2781053074 @default.
- W4313373552 hasConcept C502942594 @default.
- W4313373552 hasConcept C71924100 @default.
- W4313373552 hasConcept C86803240 @default.
- W4313373552 hasConcept C8891405 @default.
- W4313373552 hasConceptScore W4313373552C121608353 @default.
- W4313373552 hasConceptScore W4313373552C126322002 @default.
- W4313373552 hasConceptScore W4313373552C143998085 @default.
- W4313373552 hasConceptScore W4313373552C203014093 @default.
- W4313373552 hasConceptScore W4313373552C2775949291 @default.
- W4313373552 hasConceptScore W4313373552C2776256026 @default.
- W4313373552 hasConceptScore W4313373552C2777701055 @default.
- W4313373552 hasConceptScore W4313373552C2780030458 @default.
- W4313373552 hasConceptScore W4313373552C2780674031 @default.
- W4313373552 hasConceptScore W4313373552C2780851360 @default.
- W4313373552 hasConceptScore W4313373552C2781053074 @default.
- W4313373552 hasConceptScore W4313373552C502942594 @default.
- W4313373552 hasConceptScore W4313373552C71924100 @default.
- W4313373552 hasConceptScore W4313373552C86803240 @default.
- W4313373552 hasConceptScore W4313373552C8891405 @default.
- W4313373552 hasIssue "1_Supplement" @default.
- W4313373552 hasLocation W43133735521 @default.
- W4313373552 hasOpenAccess W4313373552 @default.
- W4313373552 hasPrimaryLocation W43133735521 @default.
- W4313373552 hasRelatedWork W2312518973 @default.
- W4313373552 hasRelatedWork W2318567272 @default.
- W4313373552 hasRelatedWork W2493521471 @default.
- W4313373552 hasRelatedWork W2546607321 @default.
- W4313373552 hasRelatedWork W2584071843 @default.
- W4313373552 hasRelatedWork W2623964361 @default.
- W4313373552 hasRelatedWork W3011519715 @default.
- W4313373552 hasRelatedWork W3215044659 @default.
- W4313373552 hasRelatedWork W4313373552 @default.
- W4313373552 hasRelatedWork W4322754005 @default.
- W4313373552 hasVolume "204" @default.
- W4313373552 isParatext "false" @default.
- W4313373552 isRetracted "false" @default.
- W4313373552 workType "article" @default.